Myocardial Injury after Noncardiac Surgery
Conditions
Brief summary
Myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery
Detailed description
Secondary outcomes at 30 days include: a composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest; vascular death; MINS not fulfilling the criteria of myocardial infarction; myocardial infarction; days alive and at home; stroke, health-related quality of life; cancellation/postponement of surgery on the day of surgery due to HR concerns; intraoperative mean arterial pressure; intraoperative heart rate; clinically important atrial fibrillation; safety outcomes including clinically significant bradycardia, clinically significant hypotension and phosphenes.
Interventions
DRUGIvabradine Anpharm 5 mg film-coated tablets
DRUGPlacebo: lactose monohydrate
DRUGmicrocrystalline cellulose
DRUGmaltodextrin
DRUGmagnesium stearate
Capsule: Beef gelatin
DRUGGlycerol
DRUGTitanium dioxide
Sponsors
Uniwersytet Jagiellonski Collegium Medicum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes at 30 days include: a composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest; vascular death; MINS not fulfilling the criteria of myocardial infarction; myocardial infarction; days alive and at home; stroke, health-related quality of life; cancellation/postponement of surgery on the day of surgery due to HR concerns; intraoperative mean arterial pressure; intraoperative heart rate; clinically important atrial fibrillation; safety outcomes including clinically significant bradycardia, clinically significant hypotension and phosphenes. | — |
Countries
Poland
Outcome results
None listed